How one of the EU's largest regulators is adapting to new technological demands
This article was originally published in Clinica
Executive Summary
The surge in development of innovative products in human tissue engineering, nanotechnology and other product areas on the drug/device borderline is placing increasingly tough demands on national regulators. Amanda Maxwell interviewed Professor Kent Woods, the chief executive of the UK's Medicines and Healthcare products Regulatory Agency (MHRA), to see how one of the EU's largest competent authorities is managing